1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow relmapirazin: new trials by email Literature Review of relmapirazin trials Research Report on relmapirazin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. MB-102, Fludarabine, Cyclophosphamide - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Terminated | Mustang Bio | 3 | 2020-02-17 | 2024-07-22 |
| Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types MB-102-- single dose of 4 µmol/kg, MB-102-- single dose of 130 mg, MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart - Acute Kidney Injury | Phase 2 | Completed | MediBeacon | 234 | 2016-05-11 | 2023-10-26 |
Acute Kidney Injury (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1)
MediBeacon (1) · Mustang Bio (1)
United States (2)
Lihua E Budde, MD (1) · Richard B Dorshow, PhD (1)